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Perspective: Some prior experimental and clinical studies have
demonstrated improved outcomes after OHCA when CPR is
performed for 3 minutes before rhythm analysis (and defibril-
lation if appropriate). This study provides strong evidence
against a beneficial effect of additional CPR before initial
rhythm analysis. The results suggest that there is no reason to
defer rhythm analysis and defibrillation once the chest elec-
trodes are in place.
Summary written by: Fred Morady, MD
Reversal of Rivaroxaban and Dabigatran by
Prothrombin Complex Concentrate: A Randomized,
Placebo-Controlled, Crossover Study in Healthy
Subjects
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller
HR, Levi M.
Circulation 2011;Sep 6:[Epub ahead of print].
Study Question: What is the potential of prothrombin com-
plex concentrate (PCC) to reverse the anticoagulant effect
of rivaroxaban or dabigatran? 
Methods: The authors reported the results of a randomized,
double-blind, placebo-controlled, crossover trial in 12
healthy male subjects receiving rivaroxaban 20 mg twice
daily (n = 6) or dabigatran 150 mg twice daily (n = 6) for 2.5
days, followed by either a single bolus of 50 IU/kg PCC
(Cofact) or a similar volume of saline. After a washout
period of 11 days, the groups were crossed over, and the
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Arrhythmias
Early Versus Later Rhythm Analysis in Patients
With Out-of-Hospital Cardiac Arrest
Stiell IG, Nichol G, Leroux BG, et al., on behalf of the ROC
Investigators.
N Engl J Med 2011;365:787-797.
Study Question: Is survival after out-of-hospital cardiac arrest
(OHCA) affected by the duration of manual cardiopul-
monary resuscitation (CPR) before initial rhythm analysis? 
Methods: This prospective study was performed by the
Resuscitation Outcomes Consortium in 9,933 patients
(mean age 67 years) with OHCA. Upon arrival of emer-
gency medical services (EMS), the patients were randomly
assigned to early rhythm analysis (30-60 seconds of CPR
before rhythm analysis, n = 5,290) or delayed rhythm analy-
sis (180 seconds of CPR before rhythm analysis, n = 4,643).
The primary outcome was survival to hospital discharge with
satisfactory functional status. 
Results: The median time to rhythm analysis was 42 seconds
in the early-analysis group and 180 seconds in the later-
analysis group. Survival to hospital discharge with
satisfactory functional status was 5.9% in both groups. 
Conclusions: Survival after OHCA is not improved by length-
ening the amount of EMS-administered CPR from 30-60
seconds to 180 seconds before rhythm analysis. 
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secondary diagnoses codes, the principal procedure code and
secondary procedure codes, discharge status, a four-digit
unique facility identifier, and the license number of the
operating physician. To test the effects of report cards on
hospital-level volume, the authors use the number of CABG
procedures performed in a hospital in a quarter as the
dependent variable. They use regression equation using the
number of CABG procedures performed by a surgeon in a
quarter as the dependent variable to test the effects of report
cards on surgeon-level volume.
Results: The results suggest that being identified as a high-
mortality hospital in the most recent report card is associated
with a decline of nine CABG surgeries per quarter. This
decline is not statistically significant. For all CABG cases,
being identified as a high-mortality surgeon was associated
with a decline of 4.76 CABG surgeries per quarter, and the
coefficient was significant at the 1% level. Being identified
as a low-mortality surgeon was associated with an increase of
4.63 CABG surgeries per quarter, though this coefficient
was not precisely estimated. 
Conclusions: The authors found a reduction in volume of poor
performing and unrated surgeons’ volume, but no effect on
more highly rated surgeons or hospitals of any report card
rating. 
Perspective: The study reports that public reporting led to a
decrease in volume for unrated and poor performing sur-
geons, but interestingly, the volume of the high performing
surgeons does not increase by an offsetting amount. Results
of the patient choice modeling suggest that public reporting
leads to avoidance of poor performing or unrated surgeons.
Additional research is needed to assess the degree to which
report cards affect total welfare, as well as examining the
mechanisms by which the report cards lead to the sorting
and avoidance behavior reported in this study.
Summary written by: Debabrata Mukherjee, MD
Incidence of Aortic Complications in Patients With
Bicuspid Aortic Valves
Michelena HI, Khanna AD, Mahoney D, et al.
JAMA 2011;306:1104-1112.
Study Question: What is the incidence of aortic complications
in patients with bicuspid aortic valve (BAV), in a commu-
nity cohort and in the general population? 
Methods: The investigators conducted a comprehensive
assessment of aortic complications of patients with BAV liv-
ing in a population-based setting in Olmsted County, MN.
They analyzed long-term follow-up of a cohort of all
Olmsted County residents diagnosed with definite BAV by
echocardiography from 1980 to 1999, and searched for aor-
tic complications of patients whose bicuspid valves had gone
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protocol repeated. Anticoagulant effect of rivaroxaban was
assessed with prothrombin time (PT) and thrombin genera-
tion, as measured by the endogenous thrombin potential
(ETP). Dabigatran effect was measured by activated partial
thromboplastin time (aPTT), ecarin clotting time (ECT),
and thrombin time (TT). 
Results: PT was prolonged by rivaroxaban (15.8 ± 1.3 vs.
12.3 ± 0.7 seconds at baseline; p < 0.001) that was immedi-
ately reversed by PCC (12.8 ± 1.0; p < 0.001). ETP was
inhibited by rivaroxaban (51 ± 22%; baseline, 92 ± 22%; p =
0.002) and normalized with PCC (114 ± 26%; p < 0.001).
No effect was seen with saline placebo. There was a signifi-
cant, immediate increase in aPTT, ECT, and TT by
dabigatran. PCC had little effect on these parameters after
dabigatran. 
Conclusions: PCC immediately and completely reverses the
anticoagulant effect of rivaroxaban in healthy subjects, but
has no influence on the anticoagulant action of dabigatran
at the PCC dose used in this study.
Perspective: This important study is a systematic attempt to
answer an essential question regarding the two newest Food
and Drug Administration (FDA) approved anticoagulants for
clinical use in this country. As these agents are rapidly
adopted for clinical use, and indications approved by the FDA
expand, the need to assess and reverse their effect will be
increasingly important. At this point, highly effective solu-
tions are identified for rivaroxaban, while dabigatran remains
without any identified reversal agent. Further evaluation is
needed, given the widespread indications for these agents.
Summary written by: James B. Froehlich, MD, MPH
Cardiovascular Surgery
Do Bad Report Cards Have Consequences?
Impacts of Publicly Reported Provider Quality
Information on the CABG Market in Pennsylvania
Wang J, Hockenberry J, Chou SY, Yang M.
J Health Econ 2011;30:392-407.
Study Question: What is the impact of coronary artery bypass
grafting (CABG) report cards on a provider’s aggregate vol-
ume and volume by patient severity?
Methods: The investigators employed four different data sets
in this study. The primary data are the Pennsylvania
Inpatient Hospital Discharge Data collected by the
Pennsylvania Health Care Cost Containment Council
(PHC4). This data set contains clinical and utilization
information at the patient level. Data elements include
patients’ race/ethnicity, gender, age, zip code of residence,
severity of illness, insurance type, the type of admission, the
quarter of admission, the principal diagnosis code and 
Methods: ASCOT enrolled subjects with total cholesterol
levels ≤250 mg/dl, who were then randomized to atorvas-
tatin (10 mg/day) or placebo. All subjects had a diagnosis of
hypertension and three or more additional cardiovascular
disease (CVD) risk factors. At baseline, participants had no
history of myocardial infarction or currently treated angina.
This was a case-controlled study of 485 CVD cases that
were matched by age, sex, and study entry time, to 1,367
controls.   
Results: Over a median follow-up of 5.5 years, 1,852 subjects
were eligible for inclusion in this current analysis; 131 were
excluded for missing values. The mean age was 64.7 years,
and 84.7% were male. Baseline low-density lipoprotein
(LDL) levels and log-transformed CRP were predictive of
CVD events (odds ratio [OR], 1.31). Inclusion of CRP into
the Framingham risk model improved risk prediction mod-
estly. There was no evidence of an interaction between LDL
and CRP and treatment effect on CVD events. A 6-month
on-treatment LDL among those randomized to atorvastatin
was associated with a significant reduction in CVD events
(OR, 0.41). In contrast, CRP below the median (1.83
mg/L) compared with CRP above the median was not asso-
ciated with a significant reduction in CVD events (OR,
0.86). 
Conclusions: Among hypertensive patients with additional
CVD risk factors, CRP did not improve prediction of
events in a clinically meaningful way. Reduction in CRP
associated with statin therapy was not a predictor of CVD
outcomes alone or in combination with LDL levels. 
Perspective: This is an interesting finding. Using data from
ASCOT, these results support the continued use of traditional
risk factors as a means of identifying patients at increased risk
for CVD outcomes.
Summary written by: Elizabeth A. Jackson, MD
ESC Guidelines for the Management of Acute
Coronary Syndromes in Patients Presenting
Without Persistent ST-Segment Elevation: The Task
Force for the Management of Acute Coronary
Syndromes (ACS) in Patients Presenting Without
Persistent ST-Segment Elevation of the European
Society of Cardiology (ESC)
Hamm CW, Bassand JP, Agewall S, et al.
Eur Heart J 2011;Aug 26:[Epub ahead of print]. 
Perspective: The following are 10 points to remember from
these European Society of Cardiology guidelines:  
1: Acute coronary syndrome (ACS) is usually precipitated by
acute thrombosis induced by a ruptured or eroded
undiagnosed. The last year of follow-up was 2008-2009.
The main outcome measures were thoracic aortic dissection,
ascending aortic aneurysm, and aortic surgery. 
Results: The cohort included 416 consecutive patients with
definite BAV, mean follow-up of 16 years (6,530 patient-
years). Aortic dissection occurred in 2 of 416 patients;
incidence of 3.1 cases per 10,000 patient-years, age-adjusted
relative-risk 8.4 compared with the county’s general popula-
tion. Aortic dissection incidences for patients 50 years or
older at baseline and bearers of aortic aneurysms at baseline
were 17.4 and 44.9 cases per 10,000 patient-years, respec-
tively. Comprehensive search for aortic dissections in
undiagnosed bicuspid valves revealed two additional
patients, allowing estimation of aortic dissection incidence
in bicuspid valve patients irrespective of diagnosis status,
which was similar to the diagnosed cohort. Of 384 patients
without baseline aneurysms, 49 developed aneurysms at fol-
low-up, incidence of 84.9 cases per 10,000 patient-years and
an age-adjusted relative risk 86.2. The 25-year rate of aortic
surgery was 25%. 
Conclusions: In the population of patients with BAV, the
incidence of aortic dissection over a mean of 16 years of fol-
low-up was low, but significantly higher than in the general
population. 
Perspective: This study suggests that patients with BAV
develop a clinical aortopathy that affects clinical outcome. The
dissection incidence was higher in patients older than 50 years
and higher in those with baseline aortic aneurysms, highlight-
ing the importance of close monitoring and implementation of
current guidelines in these subgroups. Future research should
focus on elucidating biological pathways of BAV aortopathy
amenable to medical treatment, as well as identifying novel
markers for refining risk prediction of aortic dissection in
these patients. 
Summary written by: Debabrata Mukherjee, MD
General Cardiology
Evaluation of C-Reactive Protein Prior to and On-
Treatment as a Predictor of Benefit From
Atorvastatin: Observations From the Anglo-
Scandinavian Cardiac Outcomes Trial
Sever PS, Poulter NR, Chang L, et al., on behalf of the ASCOT
Investigators.
Eur Heart J 2011;Jul 28:[Epub ahead of print].
Study Question: Among subjects enrolled in the ASCOT
trial, was C-reactive protein (CRP) associated with
increased risk of cardiovascular outcomes?
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atherosclerotic coronary plaque, with or without concomi-
tant vasoconstriction, causing a sudden and critical
reduction in blood flow. 
2: Blood has to be drawn promptly for troponin measure-
ment. The result should be available within 60 minutes. The
test should be repeated 6-9 hours after initial assessment if
the first measurement is not conclusive. Repeat testing after
12-24 hours is advised if the clinical condition is still sug-
gestive of ACS. 
3: Angiography should be performed urgently for diagnostic
purposes in patients at high risk and in whom the differential
diagnosis is unclear. Coronary computed tomography angiog-
raphy should be considered to exclude ACS when there is a
low to intermediate likelihood of coronary artery disease, and
when troponin and electrocardiogram are inconclusive. 
4: Quantitative assessment of risk is useful for clinical deci-
sion making. The GRACE risk score provides the most
accurate stratification of risk both on admission and at dis-
charge. 
5: Ticagrelor (180 mg loading dose, 90 mg twice daily) is rec-
ommended for all patients at moderate to high risk of
ischemic events, regardless of initial treatment strategy and
including those pretreated with clopidogrel. 
6: Prasugrel (60 mg loading dose, 10 mg daily dose) is rec-
ommended for P2Y12-inhibitor-naïve patients in whom
coronary anatomy is known and who are proceeding to per-
cutaneous coronary intervention (PCI), unless there is a
high risk of life-threatening bleeding or other contraindica-
tions. 
7: Clopidogrel (300 mg loading dose, 75 mg daily dose) is rec-
ommended for patients who cannot receive ticagrelor or
prasugrel. 
8: Fondaparinux (2.5 mg subcutaneously daily) is recom-
mended as having the most favorable efficacy–safety profile
with respect to anticoagulation. If the initial anticoagulant is
fondaparinux, a single bolus of unfractionated heparin (85
IU/kg adapted to activated clotting time) should be added at
the time of PCI.
9: Urgent coronary angiography (<2 hours) is recommended in
patients at very high ischemic risk (refractory angina, with
associated heart failure, life-threatening ventricular arrhyth-
mias, or hemodynamic instability). 
10: Appropriate secondary prevention is of paramount impor-
tance since ischemic events continue to accrue at a high rate
after the acute phase.
Summary written by: Debabrata Mukherjee, MD
Statins and Intracerebral Hemorrhage: A
Retrospective Cohort Study
Hackam DG, Austin PC, Huang A, et al.
Arch Neurol 2011;Sep 12:[Epub ahead of print].
Study Question: What is the association between statins and
intracerebral hemorrhage (ICH) in patients with recent
ischemic stroke in a population-based setting?
Methods: This was a retrospective propensity-matched cohort
study with accrual from July 1, 1994 to March 31, 2008, in
Ontario, Canada. A total of 17,872 patients ages 66 years
and older who initiated statin therapy following acute
ischemic stroke were followed for a median of 4.2 years.
Main outcome measures were hospitalization or emergency
department visit for ICH defined using validated diagnosis
coding. 
Results: Overall, 213 episodes of ICH occurred. In the pri-
mary analysis comparing statin users with nonusers, authors
found no association between statins and ICH (hazard ratio,
0.87; 95% confidence interval, 0.65-1.17). Subgroup and
dose-response analyses yielded similar results. In tests of
specificity, statin therapy was not associated with bone min-
eral density testing, vitamin D or B12 screening,
gastrointestinal endoscopy, or elective knee arthroplasty, sug-
gesting that results were not due to healthy user bias or
differences in quality of care. 
Conclusions: Statin exposure following ischemic stroke was
not associated with ICH. 
Perspective: This study found no association between statins
and subsequent ICH. This lack of harmful association was
maintained across subgroup analyses, and irrespective of
statin dosing. Based on these data and the meta-analysis of
statin trials from the Cholesterol Treatment Trialists’
Collaboration, clinicians should continue to adhere to cur-
rent national treatment guidelines recommending statin
therapy for most patients with a history of ischemic stroke.
Summary written by: Debabrata Mukherjee, MD 
Heart Failure/Transplant
Management of Chronic Heart Failure in Adults:
Synopsis of the National Institute for Health and
Clinical Excellence Guideline
Mant J, Al-Mohammad A, Swain S, Laramee P, on behalf of the
Guideline Development Group.
Ann Intern Med 2011;155:252-259.
Conclusions: The following are points to remember about the
management of chronic heart failure (HF) in adults: 
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N-Terminal Pro-Brain Natriuretic Protein Levels in
Takotsubo Cardiomyopathy
Nguyen TH, Neil CJ, Sverdlov AL, et al.
Am J Cardiol 2011;Aug 24:[Epub ahead of print].
Study Question: Do N-terminal probrain natriuretic peptide
(NT-proBNP) levels correlate with inflammatory markers,
catecholamines, and/or cardiopulmonary hemodynamics in
takotsubo cardiomyopathy (TCC)? 
Methods: Patients (n = 56) with TCC underwent echocardio-
graphy and laboratory assessment (NT-proBNP, troponin,
C-reactive protein, normetenephrine levels) at baseline, 10
days, and 3 months after diagnosis. All patients underwent
angiogram at baseline to exclude significant coronary disease;
34 had a right heart catheterization and 42 had cardiac mag-
netic resonance imaging on index presentation. Correlations
between NT-proBNP, baseline wedge pressure, wall stress
by MRI, and wall motion score index by echocardiogram
were examined.
Results: The mean patient age was 69 years, 96% (n = 54)
were female, and 81% had experienced an acute stressor in
life. At baseline, mean left ventricular ejection fraction
(LVEF) was 53 ± 13%, 100% had an elevation of troponin T
(median 0.32), and 36% had ST elevation on admission elec-
trocardiogram. Median baseline NT-proBNP level was 1325
pg/ml) at presentation, and levels increased significantly
(NT-proBNP 4382 pg/ml) within 24 hours of presentation,
with a slow and incomplete normalization by 3 months.
Median baseline plasma norepinephrine concentrations (998
pmol/L) were significantly correlated (r = 0.53, p = 0.001)
with peak NT-proBNP levels. Correlations with C-reactive
protein were weak (r = 0.3, p = 0.05). Likewise, NT-proBNP
correlated with baseline LVEF (r = -0.39, 0.008) and the
extent of impaired wall motion (r = 0.37, p = 0.008) found
on echocardiogram. 
Conclusions: TTC is associated with elevated NT-proBNP
levels, and these levels correlate with catecholamine increases
and decrements in LV systolic function. 
Perspective: The authors provide interesting insight into TCC.
By demonstrating that NT-proBNP continues to increase
after admission, they suggest that the hormone increment is
likely the result of increased synthesis rather than release of
pre-formed peptides in response to catecholamine stress.
Since catecholamine stress is associated with myocardial cal-
cium toxicity and inflammation is a cardiac depressant,
perhaps unmeasured extracellular and intracellular biochemi-
cal imbalances and perturbations are at play in this
interesting disease.
Summary written by: Jennifer Ann Cowger, MD, MS
1: The National Institute for Health and Clinical Excellence
(NICE) develops clinical practice guidelines for the National
Health Service of England and Wales. Based on literature
searches (cut-off date, October 2009), the guidelines devel-
opment group (GDG) of NICE made new recommenda-
tions for the diagnosis and management of HF.
2: Their studies found a net savings of £19,000 per 100,000
persons if all of these recommendations were implemented. 
3: The American College of Cardiology Foundation/American
Heart Association guidelines focus on the assessment of HF
rather than determining whether a patient has this syndrome.
The European Society of Cardiology guidelines on diagnosis
recommend that all patients with symptoms suggestive of HF
undergo echocardiography and measurement of serum natri-
uretic peptide levels, whereas NICE recommends discerning
utilization of these diagnostic tests.
4: In diagnosis, the NICE guideline focuses on using both a
history of myocardial infarction and an increase in serum
natriuretic peptide levels to guide further assessment. It also
recommends time limits within which patients should
receive both echocardiography and clinical assessment by a
specialist. Their review of the literature concluded that clini-
cal signs and symptoms are of limited use in the diagnosis of
HF, and that measurement of serum natriuretic peptide lev-
els (both B-type natriuretic peptide [BNP] and N-terminal
pro-BNP) has high sensitivity, but only moderate specificity
for diagnosis of HF. 
5: The GDG encourages increased use of beta-blockers and
angiotensin-converting enzyme inhibitors as first-line therapy
in patients with HF and left ventricular systolic dysfunction,
and proposes options for second-line therapy (aldosterone
antagonists, angiotensin-receptor blockers, or combination
therapy with a nitrate and hydralazine).
Perspective: Clearly, the National Health Service has to allo-
cate scarce resources and, hence, the NICE guidelines focus
on what is cost-effective in the British system to diagnose
and treat HF. For example, there is a limited pool of spe-
cialists and cardiologists in the UK and, therefore, often the
management of milder HF has to be done by general practi-
tioners. Therefore, these guidelines may be appropriate in
the UK, where resource allocation has to be done in a meas-
ured fashion. However, the cumulative risk reduction if all
of the three therapies (i.e., ACE inhibitors, beta-blockers,
and aldosterone receptor blockers) are used was 63% and
absolute risk reduction was 22%. Therefore, the number
needed to treat = 5 (Fonarow G, et al., Braunwald’s Atlas of
Heart Diseases, Volume 15, Chapter 5, Current Medicine).
Summary written by: Ragavendra R. Baliga, MBBS
JACC Vol. 58, No. 19, 2011
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Clopidogrel Pre-Treatment Is Associated With
Reduced In-Hospital Mortality in Primary
Percutaneous Coronary Intervention for Acute
ST-Elevation Myocardial Infarction
Dörler J, Edlinger M, Alber HF, et al., on behalf of the Austrian
Acute PCI Investigators.
Eur Heart J 2011;Sep 14:[Epub ahead of print].
Study Question: What is the clinical benefit of preloading with
clopidogrel in patients undergoing primary percutaneous
coronary intervention (PCI) for ST-segment elevation
myocardial infarction (STEMI)? 
Methods: The authors compared the outcome of patients pre-
treated with clopidogrel (prior to arrival at the PCI center)
with those who were not preloaded prior to undergoing pri-
mary PCI. All patients were enrolled in the Austrian Acute
PCI registry. 
Results: Of the 5,955 patients who underwent primary PCI,
1,635 patients were pretreated with clopidogrel. Patients
pretreated with clopidogrel were less likely to be in cardio-
genic shock (8.4% vs. 11.2%) or require cardiopulmonary
resuscitation prior to PCI (5.2% vs. 9.6%). Clopidogrel pre-
treatment was associated with lower in-hospital mortality
(3.4 vs. 6.1%, p < 0.01) after primary PCI. After adjusting
for baseline differences, clopidogrel pretreatment was an
independent predictor of lower in-hospital mortality. This
difference was more pronounced in the patients who were
treated with platelet glycoprotein IIb/IIIa inhibitors in the
catheterization laboratory.
Conclusions: Clopidogrel pretreatment is associated with a
lower mortality among patients undergoing primary PCI for
STEMI. 
Perspective: This study suggests that clopidogrel preloading is
associated with a dramatic reduction in in-hospital mortality
among patients undergoing primary PCI. Clopidogrel pre-
loading was more commonly performed in patients who were
less sick, and it is not clear if the findings of this study reflect
immigration bias and residual confounding or a true survival
benefit of early clopidogrel. 
Summary written by: Hitinder S. Gurm, MBBS
Stenting Versus Aggressive Medical Therapy for
Intracranial Arterial Stenosis
Chimowitz MI, Lynn MJ, Derdeyn CP, et al., on behalf of the
SAMMPRIS Trial Investigators.
N Engl J Med 2011;Sep 7:[Epub ahead of print].
Study Question: What is the role of percutaneous transluminal
angioplasty and stenting (PTAS) for intracranial arterial
stenosis?
Methods: The investigators randomly assigned patients who
had a recent transient ischemic attack or stroke attributed to
stenosis of 70-99% of the diameter of a major intracranial
artery to aggressive medical management alone, or aggressive
medical management plus PTAS with the use of the
Wingspan stent system. The primary endpoint was stroke or
death within 30 days after enrollment or after a revasculariza-
tion procedure for the qualifying lesion during follow-up, or
stroke in the territory of the qualifying artery beyond 30 days. 
Results: Enrollment was stopped after 451 patients under-
went randomization, because the 30-day rate of stroke or
death was 14.7% in the PTAS group (nonfatal stroke,
12.5%; fatal stroke, 2.2%) and 5.8% in the medical-manage-
ment group (nonfatal stroke, 5.3%; non–stroke-related
death, 0.4%). Beyond 30 days, stroke in the same territory
occurred in 13 patients in each group. The mean duration of
follow-up, which is ongoing, is 11.9 months. The probabil-
ity of the occurrence of a primary endpoint event over time
differed significantly between the two treatment groups (p =
0.009), with 1-year rates of the primary endpoint of 20.0%
in the PTAS group and 12.2% in the medical-management
group. 
Conclusions: In patients with intracranial arterial stenosis,
aggressive medical management was superior to PTAS. 
Perspective: This study suggests that aggressive medical therapy
was superior to PTAS in high-risk patients with intracranial
stenosis, because the rate of periprocedural stroke after PTAS
was higher than expected and the rate of stroke in the med-
ical-management group was lower than estimated. Essential
elements of the aggressive medical regimen used in this trial
can readily be adopted in clinical practice, including adding
clopidogrel to aspirin for the first 90 days and lowering blood
pressure and low-density lipoprotein cholesterol to achieve
target levels based on national guidelines. 
Summary written by: Debabrata Mukherjee, MD
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Prevention/Vascular
High Residual Platelet Reactivity After Clopidogrel
Loading and Long-Term Cardiovascular Events
Among Patients With Acute Coronary Syndromes
Undergoing PCI 
Parodi G, Marcucci R, Valenti R, et al.
JAMA 2011;306:1215-1223.
Study Question: Is high residual platelet reactivity (HRPR) an
independent prognostic marker of risk of long-term throm-
botic events in patients with acute coronary syndromes (ACS)
undergoing an invasive procedure? 
Methods: This was a prospective, observational, referral center
cohort study of 1,789 consecutive patients with ACS under-
going percutaneous coronary intervention (PCI) from April
2005 to April 2009, at the Division of Cardiology of
Careggi Hospital, Florence, Italy, in whom platelet reactiv-
ity was prospectively assessed by light transmittance
aggregometry. All patients received 325 mg of aspirin and a
loading dose of 600 mg of clopidogrel, followed by a main-
tenance dosage of 325 mg/d of aspirin and 75 mg/d of
clopidogrel for at least 6 months. Patients with HRPR, as
assessed by adenosine diphosphate (ADP) test (≥70%
platelet aggregation), received an increased dose of clopido-
grel (150-300 mg/d) or switched to ticlopidine (500-1000
mg/d) under ADP test guidance. The primary endpoint was
a composite of cardiac death, myocardial infarction, any
urgent coronary revascularization, and stroke at 2-year fol-
low-up. Secondary endpoints were stent thrombosis and
each component of the primary endpoint. 
Results: The primary endpoint event rate was 14.6%
(36/247) in patients with HRPR and 8.7% (132/1,525) in
patients with low residual platelet reactivity. Stent thrombo-
sis was higher in the HRPR group compared with the low
residual platelet reactivity group (6.1% vs. 2.9% ). By multi-
variable analysis, HRPR was independently associated with
the primary endpoint and with cardiac mortality. 
Conclusions: Among patients receiving platelet reactivity–
guided antithrombotic medication after PCI, HRPR status
was significantly associated with increased risk of ischemic
events at short- and long-term follow-up. 
Perspective: This study also suggests that normalization of the
ADP test result after treatment adjustment is not associated
with better outcome versus a persistent abnormal ADP test
result. It remains to be seen if HRPR after 600 mg clopido-
grel loading in patients undergoing PCI for ACS is a non-
modifiable risk factor for thrombotic events or if tailored
therapy with use of newer, more potent antithrombotic agents
such as prasugrel or ticagrelor may have a beneficial effect on
clinical outcome in these patients.
Summary written by: Debabrata Mukherjee, MD
General and Abdominal Obesity and Risk of Death
Among Black Women
Boggs DA, Rosenberg L, Cozier YC, et al.
N Engl J Med 2011;365:901-908.
Study Question: What is the relation of general and abdomi-
nal obesity to the risk of death in black women? 
Methods: The investigators prospectively assessed the relation
of both body mass index (BMI) and waist circumference to
the risk of death among 51,695 black women with no his-
tory of cancer or cardiovascular disease who were 21-69
years of age at study enrollment. Their analysis was based
on follow-up data from 1995 through 2008 in the Black
Women’s Health Study. 
Results: Of 1,773 deaths identified during follow-up, 770
occurred among 33,916 women who had never smoked.
Among nonsmokers, the risk of death was lowest for a BMI
of 20.0-24.9. For a BMI above this range, the risk of death
increased as the BMI increased. With a BMI of 22.5-24.9
as the reference category, multivariable-adjusted hazard
ratios were 1.12 for a BMI of 25.0-27.4, 1.31 for a BMI of
27.5-29.9, 1.27 for a BMI of 30.0-34.9, 1.51 for a BMI of
35.0-39.9, and 2.19 for a BMI of 40.0-49.9 (p < 0.001 for
trend). A large waist circumference was associated with an
increased risk of death from any cause among women with a
BMI of <30.0. 
Conclusions: The risk of death from any cause among black
women increased with an increasing BMI of 25.0 or higher.  
Perspective: This large prospective study suggests that the
risk of death from any cause among black women was low-
est among women with a BMI of 20.0-24.9, with an
increased risk of death for all categories of BMI in the over-
weight and obesity range. A larger waist circumference was
associated with an increase in the risk of death from any
cause only among nonobese nonsmokers. Future studies will
need to assess the survival advantage conferred on those
individuals who lose weight.
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Meta-Analysis Comparing Mediterranean to
Low-Fat Diets for Modification of Cardiovascular
Risk Factors
Nordmann AJ, Suter-Zimmermann K, Bucher HC, et al.
Am J Med 2011;124:841-851.
Study Question: What is the relative value of a Mediterranean
diet compared to low-fat diets for modifying cardiovascular
risk factors? 
Methods: MEDLINE, EMBASE, Biosis, Web of Science,
and the Cochrane Central Register of Controlled Trials were
searched from their inception until January 2011. Addition-
ally, experts in the field were asked to identify randomized
controlled trials (RCTs) comparing Mediterranean to low-
fat diets in overweight/obese individuals, with a minimum
follow-up of 6 months, reporting intention-to-treat data on
cardiovascular risk factors. Two authors independently
assessed trial eligibility and quality. 
Results: Six RCTs were identified that included 2,650 indi-
viduals (50% women). Mean age of enrolled patients ranged
from 35 to 68 years, and mean body mass index from 29 to
35 kg/m2. After 2 years of follow-up, individuals assigned to
a Mediterranean diet had more favorable changes in
weighted mean differences of body weight (-2.2 kg), body
mass index (-0.6 kg/m2), systolic blood pressure (-1.7 mm
Hg), diastolic blood pressure (-1.5 mm Hg), fasting plasma
glucose (-3.8 mg/dl), total cholesterol (-7.4 mg/dl), and
high-sensitivity C-reactive protein (-1.0 mg/L). The
observed heterogeneity across individual trials could be elim-
inated by restricting analyses to trials with balanced
co-interventions or trials with restriction of daily calorie
intake in both diet groups. 
Conclusions: Mediterranean diets appear to be more effective
than low-fat diets in inducing clinically relevant long-term
changes in cardiovascular risk factors and inflammatory
markers. 
Perspective: The observed differences for the individual risk
factors were modest, but would be meaningful in large
cohorts. The Lyon Diet-Heart Study (not included) found a
70% reduction in overall mortality with the Mediterranean
diet when compared to standard post-event diet recommen-
dations in survivors of a myocardial infarction. The
Mediterranean diet was posited to be of value when the risk
of cardiovascular events was found to be low in men from
the island of Crete. The contents of value include high fiber,
fruits and vegetables, fish, and wine.
Summary written by: Melvyn Rubenfire, MD
Effects of a Home-Based Walking Intervention on
Mobility and Quality of Life in People With Diabetes
and Peripheral Arterial Disease: A Randomized,
Controlled Trial
Collins TC, Lunos S, Carlson T, et al.
Diabetes Care 2011;Aug 26:[Epub ahead of print].
Study Question: What is the efficacy of a home-based walking
intervention to improve walking ability and quality of life in
people with diabetes and peripheral arterial disease (PAD)?
Methods: This was a multisite controlled, single-blind trial
in which 145 patients (45 women) with diabetes and PAD
were randomized to the intervention (a 6-month behavioral
intervention targeting levels of readiness to engage in rou-
tine walking for exercise) versus attention control. Primary
outcome was 6-month change in maximal treadmill walk-
ing distance. Secondary outcomes included 3-month change
in maximal walking distance, lower limb function (i.e.,
walking impairment scores), quality of life (Medical
Outcomes Short Form Survey), exercise behaviors, depres-
sive symptoms, and self-efficacy at 3 and 6 months.
Results: The mean age of participants was 66.5 years.
Intervention and control groups did not differ significantly
in 6-month change in maximal treadmill walking distance
(average 24.5 m vs. 39.2 m; p = 0.60). Among secondary
outcomes, for the intervention and control groups, respec-
tively, average walking speed scores increased by 5.7 units
and decreased by 1.9 units (p = 0.03); the mental health
quality of life subscale score increased by 3.2 and decreased
by 2.4 units (p = 0.01). 
Conclusions: A home-based walking intervention did not
improve walking distance, but did improve walking speed and
quality of life in people with diabetes and PAD. Clinicians
should consider recommending home-based walking therapy
for such patients. 
Perspective: While the results are disappointing, the improve-
ment in walking speed and quality of life are impressive,
considering that all the patients were diabetics. The program
included counseling for exercise intervention, two walking
training sessions with an instructor, and individual and group
walking in the community. This would be considerably less
costly compared to onsite supervised PAD rehabilitation.
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